Analyst Coverage

The following research analysts cover Destiny Pharma:

Brian White, Shore Capital +44(0)20 7408 4050
Karl Keegan, Singer Capital Markets +44(0)20 7496 3187
Adam McCarter, Cavendish Capital Markets +44(0)20 7220 0500
Andy Smith, Equity Development +44(0)20 7065 2690
Dominic Rose, Intron Health +44(0)20 8156 7791

 

Please click on links below to access coverage published:

Shore Capital Markets

31 January 2024 – Pipeline progress
25 October 2023 – XF-73 perfectly positioned

Cavendish Capital Markets

4 January 2024 – Maximising XF-73 nasal value the priority for 2024
23 October 2023 – Capital markets day shines a light on the XF-pipeline

Equity Development Equity Development

31 January 2024 – Clinical Development Updates
20 October 2023 – XF-73 is ‘The Real Deal’

Intron Health

10 August 2023 – Building An Infection Prevention Powerhouse

Destiny Pharma - Proactive Proactive Investors

For further commentary and interviews, please visit the Destiny Pharma page at Proactive Investors on the link above

Destiny Pharma Vox Markets VOX Markets

For further commentary and interviews, please visit the Destiny Pharma page at Vox Markets on the link above